When registering biosynthetic Pro-Xylane as a new cosmetic ingredient with the NMPA (National Medical Products Administration), safety verification always takes precedence over efficacy claims. While biosynthetic Pro-Xylane boasts prominent advantages in purity and chiral selectivity compared with chemically synthesized alternatives, regulators focus on three core risk dimensions: the safety of fermentation strains, residual risk substances in final products, and potential risks of sensitization and genotoxicity.
This article systematically breaks down theadditional safety evidence and exclusive toxicological data mandatory for the filing of biosynthetic Pro-Xylane, clarifying the differentiated compliance requirements for bio-based cosmetic new ingredients.
1. Ingredient Classification: The Premise of Confirming Data Requirements
China adopts a risk-based classified management system for new cosmetic ingredient registrations. The submission scope of technical and toxicological data is determined by the ingredient's production process, source attributes, and risk level.
Process Classification: Biotech-Derived New Ingredient
Biosynthetic Pro-Xylane is defined as a biotechnological new cosmetic ingredient, as its production relies on genetic engineering and microbial fermentation technologies. Unlike chemically synthesized ingredients that only require basic technical documents, biotech-derived ingredients mandate additional verification covering strain origin, fermentation process control, and bioprocess-specific residual risks.
Risk Scenario Classification: Scenario 2 Standard Application
Pro-Xylane is generally categorized under Scenario 2 for new cosmetic ingredient filing: ingredients used for the first time domestically and internationally, with no special functions such as preservation, sun protection, or coloration. Scenario 2 requires the most comprehensive set of toxicological data, covering all core safety testing items.
Key Exemption Rules
Partial toxicological testing can be exempted only if the ingredient possesses more than 3 years of verified safe cosmetic use history or safe edible history. Valid exemption supporting documents must include authoritative data such as the launch time of marketed products and cumulative sales volume, forming a high threshold for exemption application.
2. Unique Impurity Profile: Exclusive Compliance Assessment for Biosynthetic Pathways
The impurity risk spectrum of biosynthetic Pro-Xylane differs fundamentally from chemically synthesized products, constituting the core "special assessment item" for biotech ingredient registration.
Chemical Synthesis Risk Focus
Residual risks mainly cover starting materials, chemical auxiliaries, reaction intermediates, and byproducts of organic synthesis.
Biosynthesis Additional Risk Focus (Mandatory Supplementary Data)
Beyond conventional chemical impurities, biosynthetic Pro-Xylane requires full disclosure and quantitative detection of bioprocess-specific risk substances:
Strain qualification data: Complete strain source certificate, species identification report, genetic modification background and safety assessment (critical for genetically engineered strains);
Biological residue risks: Endotoxin residues, host cell protein residues, microbial fermentation metabolites, and unclassified fermentation byproducts;
Microbiological and heavy metal safety: Strict inspection for microbial contamination, prohibited cosmetic substances, and heavy metal limit compliance.
In industrial compliance practice, the routine quality control indicators for qualified biosynthetic Pro-Xylane include: heavy metal limits (Pb ≤ 10ppm, As ≤ 3ppm), zero residual organic solvents, active ingredient content deviation within ±2%, and degradation product content ≤ 0.5%.
3. A complete toxicology checkup – which items are mandatory?
According to the requirements of Scenario 2, the following toxicological test data are required for new cosmetic ingredients:
| Test Items | Specific Contents | Description |
| Acute Toxicity | Acute oral or dermal toxicity test | Determines the acute hazard level of the raw material |
| Irritation | Skin irritation test, eye irritation test | Assess exposure risk |
| Skin Sensitization | Skin allergy test | Determines whether allergies will occur |
| Phototoxicity | Skin phototoxicity test | Only required if the raw material has UV absorption properties |
| Photoallergy | Skin photoallergy test | Same as above |
| Mutagenicity | Gene mutation test + chromosomal aberration test | Assess genotoxicity risk, at least 2 items |
| Subchronic Toxicity | Subchronic oral or dermal toxicity test | Assess long-term exposure risk |
Supplementary Regulatory Rules
In the absence of authoritative transdermal absorption data of the raw material, the safety assessment adopts a default skin absorption rate of 50%. For ingredients with special molecular weight or physicochemical properties, additional in vitro skin permeation test data is required to support risk deduction.
If the fermentation strain carries potential biological risks, regulators may further supplement mandatory testing for developmental and reproductive toxicity as well as carcinogenicity.
4. Can Biosynthetic Pro-Xylane Obtain Testing Exemptions?
Compliance Advantages of High-Purity Biosynthesis
Biosynthetic technology can achieve ultra-high Pro-Xylane purity (≥99%) and a fully controllable impurity profile with fewer unknown risk substances. This enables a cleaner and more rigorous safety assessment conclusion and effectively reduces risk deduction variables.
Non-Exempt Core Testing Items
Process and purity advantages cannot replace mandatory toxicological testing. Without qualifying safe use or edible history exemption conditions, core tests including the Ames test, chromosome aberration test, and subchronic toxicity test are fully mandatory with no exemptions.
Global Upgrading of Safety Assessment Methods
Aligned with EU SCCS guidelines and updated domestic NMPA rules, modern cosmetic safety assessment systems are actively adopting animal-free alternative testing methods, such as 3D human skin model irritation tests and in vitro micronucleus assays for genotoxicity evaluation. Meanwhile, risk assessment tools including read-across analysis and Threshold of Toxicological Concern (TTC) have been widely applied to fill partial data gaps, optimizing the scientificity and efficiency of safety verification.
Summary
The core difference in registration between biosynthetic and chemically synthesized Pro-Xylane lies in bioprocess-specific safety data: strain safety certification, biological residue detection, and full impurity spectrum traceability. Ultra-high-purity biosynthesis optimizes safety attributes but does not exempt mandatory toxicological tests. The industry shift from chemical synthesis to green biosynthesis is not only a technological upgrade of ingredient efficacy and purity, but also a more standardized, transparent, and rigorous upgrade of cosmetic raw material safety compliance.
